UNITED AIRLINES THERABODY UPP KIT- sodium monofluorophosphate kit संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

united airlines therabody upp kit- sodium monofluorophosphate kit

wessco international - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - helps protect against cavities

Upstaza यूरोपीय संघ - चेक - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - metabolismus aminokyselin, vrozené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Upstaza यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - amino acid metaboliżmu, Żbalji inborn - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Upstaza यूरोपीय संघ - पुर्तगाली - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - metabolismo de aminoácidos, erros nascidos - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Upstaza यूरोपीय संघ - अंग्रेज़ी - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - amino acid metabolism, inborn errors - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.1).